Cervical Cancer treatment

Cervical cancer develops in the cervix, the lower part of the uterus connecting to the vagina. Nearly all cases (99%) result from persistent Human Papillomavirus (HPV) infection, particularly high-risk types 16 and 18. Precancerous cells (CIN) progress slowly over 10-15 years to invasive cancer if untreated.

Unlike other gynaecological cancers, cervical cancer is largely preventable through screening and vaccination. Kokilaben Dhirubhai Ambani's cervical cancer treatment achieves 90%+ cure rates for early stages, significantly higher than national averages.

Cervical cancer symptoms often appear late, making screening essential:

• Abnormal vaginal bleeding — Post-coital, intermenstrual, postmenopausal: One of the most common warning signs of cervical cancer is abnormal vaginal bleeding. This may include bleeding after sexual intercourse, bleeding between regular periods, or any bleeding after menopause. Such bleeding should never be ignored and always needs prompt evaluation by a gynaecologist.
• Vaginal discharge — Watery, foul-smelling, blood-tinged: Unusual vaginal discharge can also be a sign of cervical cancer. The discharge may be watery, have a strong or unpleasant smell, or appear mixed with blood. Persistent or changing discharge should be evaluated to rule out infections and more serious conditions, such as cancer.
• Pelvic/back pain — Advanced disease: Pain in the lower abdomen, pelvis, or lower back can occur when cervical cancer becomes more advanced. This pain may be dull, persistent, or sometimes sharp, and it may not improve with usual pain medicines. Such ongoing discomfort, especially when combined with other symptoms, needs medical assessment.
• Painful intercourse (dyspareunia): Some women with cervical cancer experience pain during sexual intercourse. This may be due to tumour growth or inflammation in the cervix and surrounding tissues. If intercourse becomes painful or there is bleeding afterwards, it is important to seek medical advice.
• Leg swelling — Lymph node obstruction: In later stages, cervical cancer can spread to nearby lymph nodes and block normal lymphatic drainage. This can cause one or both legs to swell, often accompanied by a feeling of heaviness or discomfort. A doctor should always evaluate sudden, unexplained leg swelling.
• Urinary/bowel symptoms — Bladder/rectum invasion: When cervical cancer invades nearby organs like the bladder or rectum, it can lead to urinary and bowel symptoms. These may include difficulty passing urine, blood in the urine, constipation, or pain during bowel movements. Such symptoms, especially in combination with abnormal bleeding, should prompt urgent evaluation.

In its earliest stages, cervical cancer often causes no noticeable symptoms at all. This is why many women feel completely well even when precancerous or early cancerous changes are present. Regular Pap smears and HPV tests are crucial to detect these changes early, when treatment is most effective.

Primary cause: Persistent HPV infection (types 16, 18, 31, 45).
Risk amplifiers:

• Early sexual activity (<18 years): Having sexual intercourse at a younger age increases the chance of HPV exposure when the cervix is still developing. Multiple sexual partners, or having a partner with many previous partners, further raises this risk. Practising safe sex and delaying sexual debut can help reduce the likelihood of HPV infection.
• Immunosuppression — HIV, steroids, transplant patients: Women with weak immune systems find it harder to clear HPV infections naturally. This includes those living with HIV, long-term steroid users, and organ transplant recipients on immunosuppressive medicines. As a result, they have a higher risk of persistent HPV infection and cervical cancer.
• Smoking — Carcinogens damage cervical cells: Smoking exposes the body to harmful chemicals that can damage cells, including those of the cervix. Nicotine and other toxins have been found in the cervical mucus of smokers, which can contribute to cancer development. Quitting smoking lowers the risk of many cancers, including cervical cancer.
• Long-term OCP use (>5 years): Using oral contraceptive pills (OCPs) for more than five years has been linked to a slightly higher risk of cervical cancer. This may be due to hormonal changes that make cervical cells more vulnerable to HPV. Women on long-term OCPs should be especially diligent with regular screening.
• Multiple pregnancies (>3 full-term): Having three or more full-term pregnancies may increase the risk of cervical cancer. Hormonal and immune changes during pregnancy, as well as possible repeated HPV exposure, may contribute to this risk. Regular follow-up and screening are important for women with multiple pregnancies.
• Family history — Genetic predisposition: A family history of cervical cancer can sometimes indicate a genetic susceptibility. This may mean that certain women are less able to fight off HPV or repair cell damage effectively. If a close relative has had cervical cancer, it is important to be extra cautious with screening.

HPV vaccination (Gardasil 9) prevents 90% of HPV-related cancers and is safe for ages 9-45. The HPV vaccine, such as Gardasil 9, is designed to protect against the most dangerous high-risk HPV types. When given before exposure to the virus, it can prevent up to 90% of HPV-related cervical cancers. It is safe for both girls and women aged 9–45 and is a key tool in cervical cancer prevention.

Cervical cancer screening prevents 75% of deaths:

• Pap smear: Every 3 years, ages 21-65
  A Pap smear is a simple test where cells are gently collected from the cervix and examined under a microscope. It can detect early abnormal changes long before cancer develops. Women aged 21–65 are usually advised to have a Pap test every three years if results are normal.
• HPV DNA test: Every 5 years (co-testing preferred)
  The HPV DNA test looks for the presence of high-risk HPV types directly on cervical samples. When combined with a Pap smear (co-testing), it offers very high accuracy in detecting women at risk. If both tests are normal, screening can often be safely spaced every five years.
• Visual inspection with acetic acid (VIA): Resource-limited settings
  VIA is a low-cost screening method used in areas where Pap and HPV testing may not be easily available. In this method, a dilute acetic acid (vinegar) solution is applied to the cervix and any suspicious areas turn white. It allows immediate identification and, in some cases, same-visit treatment of precancerous lesions.

CIN treatment (LLETZ, cone biopsy) cures precancerous lesions.

When screening finds Cervical Intraepithelial Neoplasia (CIN), these abnormal cells can be removed before they become cancerous. Procedures like LLETZ (large loop excision of the transformation zone) or cone biopsy precisely remove the affected area of the cervix. Most women are cured with these treatments and can return to normal life with regular follow-up.

Cervical cancer treatment by stage follows FIGO staging:

Stage I (confined to cervix):

• IA1: Microscopic invasion – Cone biopsy/fertility preservation
• IB3: 5cm – Surgery ± radiation

Stage II (upper vagina/uterus involvement): Surgery + radiation
Stage III (pelvic wall/lower 1/3 vagina): Chemoradiation
Stage IVA (bladder/rectum invasion): Palliative
Stage IVB (distant mets): Systemic therapy

Stage I 5-year survival: 93% | Stage IV: 15%

Types of treatment for cervical cancer include:

Early Stage (I - IIA):

• Fertility-sparing: Cone biopsy, radical trachelectomy
• Radical hysterectomy ± lymphadenectomy
• Simple hysterectomy (elderly/low-risk)

Locally Advanced (IB3 - IIIB):

• Chemoradiation: Cisplatin + EBRT + brachytherapy boost
• Neoadjuvant chemo surgery

Cervical cancer treatment by stage personalisation:

• Age/fertility desires – Trachelectomy vs hysterectomy: Treatment planning carefully considers a woman's age and wish to have children in the future. Younger women with early-stage disease may be offered a radical trachelectomy, which removes the cervix but preserves the uterus for possible pregnancy. In women who have completed their family or have more advanced disease, a hysterectomy (removal of the uterus) may be recommended.
• Tumour size/location – Surgery vs radiation: The size and exact location of the tumour strongly influence the choice between surgery and radiation. Small, localised tumours are often best treated with surgery, which removes the cancer in one piece. Larger or less accessible tumours may be managed more effectively with external beam radiation and brachytherapy.
• Lymphovascular invasion – Adjuvant therapy: If cancer cells are found in lymphatic or blood vessels around the tumour, the risk of spread is higher. In such cases, additional (adjuvant) treatment like radiation or chemoradiation may be advised after surgery. This approach helps reduce the chance of recurrence and improves long-term outcomes.
• HPV type – Immunotherapy eligibility: Specific high-risk HPV types and molecular markers can help guide eligibility for newer treatments, such as immunotherapy. Drugs such as pembrolizumab boost the body's immune system to recognise and attack cancer cells. These targeted options are generally considered for advanced or recurrent disease.
• Comorbidities – Treatment tolerance: Other medical conditions, such as heart disease, diabetes, kidney problems, or poor general health, can affect how well a patient tolerates treatment. Oncologists carefully review these comorbidities before finalising a plan. The goal is to choose an effective yet safe treatment that balances the chances of cure with quality of life.

At a multidisciplinary tumour board, specialists from surgery, radiation oncology, medical oncology, radiology, and pathology discuss each case. This team-based review ensures that all aspects of the disease and the patient's needs are considered. It leads to evidence-based, personalised treatment plans for every individual.

Seek specialists with:

• Gynae-oncology fellowship training
• >500 cervical cancer cases experience
• Multidisciplinary team access
• Advanced brachytherapy capability
• Fertility preservation expertise

Kokilaben Dhirubhai Ambani's team meets all criteria and publishes outcomes in international journals.

Early cervical cancer treatment transforms prognosis:

• Stage IA: 99% cure rate, fertility preservation: When cervical cancer is caught at Stage IA, it is very small and confined to the cervix. At this point, cure rates can reach 99% with appropriate treatment. Many women can also preserve their fertility through conservative surgical options.
• Stage IB: 90% 5-year survival: Even at Stage IB, outcomes remain very favourable with timely treatment. Around 90% of women are alive and disease-free at five years when managed in experienced centres. This underlines the importance of not delaying diagnosis or therapy.
• Fertility retention: 70% success with trachelectomy: Radical trachelectomy allows removal of the cancer while keeping the uterus intact in selected early-stage cases. About 70% of women who undergo this procedure and later try to conceive can achieve pregnancy. This option offers hope to young women who wish to become mothers after cancer treatment.
• Minimal side effects – Bladder/bowel function preserved: When treatment is started early and planned carefully, long-term side effects can often be minimised. Bladder and bowel functions are more likely to remain normal, and sexual function can be better preserved. Modern techniques and expertise further reduce the impact on day-to-day life.
• Shorter treatment: 4-6 weeks vs 3+ months advanced: Early-stage treatment plans are usually shorter and simpler than those needed for advanced disease. Many early cases can be treated within 4–6 weeks, while advanced stages may require three months or more of combined therapy. This shorter duration leads to faster recovery and quicker return to normal activities.

Regular screening catches changes before they turn into invasive cancer, allowing for limited, organ-sparing procedures. This means more women can keep their uterus and ovaries and avoid major surgery or intensive chemoradiation. Ultimately, screening not only prevents cancer but also protects fertility and quality of life.

Cervical cancer treatment side effects by modality:

Surgery

Lymphedema (~5%) – Swelling of one or both legs can occur if lymph nodes are removed during surgery. This happens because lymph fluid drains less efficiently. It is usually manageable with physiotherapy, compression stockings, and lifestyle measures.

Vaginal shortening – Removal of the cervix and surrounding tissues can slightly shorten or narrow the vagina. With counselling, lubricants, and pelvic floor therapy, most women can maintain comfortable sexual activity.

Radiation

Vaginal stenosis (narrowing/tightening) – Radiation can cause the vaginal walls to become less elastic and narrower over time. Regular use of vaginal dilators, lubricants, and guided sexual activity helps keep the vagina flexible and functional.

Menopause induction – When the ovaries are in the radiation field, their function may stop, leading to early menopause. This can cause hot flashes, mood changes, and vaginal dryness. Your team will discuss options like hormone replacement (if suitable) and other measures to relieve symptoms.

Chemotherapy

Nausea and vomiting – Common during treatment but now usually well controlled with modern anti-nausea medicines. Most patients can eat and drink adequately with proper support.

Hair loss (temporary) – Some chemotherapy drugs can cause thinning or loss of scalp hair. Hair almost always grows back after treatment ends, often within a few months.

Kokilaben Dhirubhai Ambani's radiation oncology services use advanced techniques such as IMRT (Intensity-Modulated Radiation Therapy) and image-guided brachytherapy to precisely target the tumour while sparing nearby healthy organs. This significantly reduces long-term bowel, bladder, and sexual side effects, helping women maintain a better quality of life after treatment.

Kokilaben Dhirubhai Ambani Hospital is a leading centre for cervical cancer treatment in Mumbai, attracting patients from across India.

• Dedicated gynae-oncology unit managing 300+ cervical cancer cases annually, ensuring high-volume, specialised experience.
• NABH-accredited cancer centre, following strict national quality and safety standards.
• Hybrid operating room with robotic hysterectomy capability for precise, minimally invasive surgery and faster recovery.
• Comprehensive radiation oncology with a modern HDR brachytherapy suite using Varian and Gammamed systems for targeted internal radiation.
• Daily multidisciplinary tumour board with gynae-oncologists, radiation oncologists, medical oncologists, radiologists, and pathologists reviewing each case.
• Recognised for fertility preservation expertise, with among the highest trachelectomy volumes in India, helping young women maintain the possibility of pregnancy.
• Outstanding outcomes: For Stage I cervical cancer, approx. 95% 5-year survival, significantly higher than the national average of ~85%.

Cervical cancer treatment demands precision, compassion, and expertise. Kokilaben Dhirubhai Ambani Hospital delivers the best treatment for cervical cancer in India through stage-specific types of treatment for cervical cancer, an advanced cancer department infrastructure, and personalised care. Early detection through our obstetrics and gynaecology clinic transforms Stage IV threats into Stage I successes.

One consultation reveals your optimal path forward. Book today.
Schedule Oncology Appointment | Cancer Helpline: +91-22-4269 6969

• 1. What is the most common cause of cervical cancer?
  Persistent HPV infection (99% of cases), high-risk types 16 and 18. HPV vaccination prevents 90%. Transmission: Sexual contact.
• 2. Can cervical cancer be cured?
  Yes, Stage I-II: 90-95% cure rates. Stage III: 60-70%. Stage IV: 20-30% 5-year survival. Early detection doubles survival.
• 3. Is HPV vaccination useful?
  Prevents 90% cervical cancers (Gardasil 9). Safe for ages 9-45, before sexual debut is optimal. 95% effective against precancerous lesions.
• 4. How long does treatment take?
  Stage I: Surgery (3-5 days hospital)
  Stage II-III: Chemoradiation (6-8 weeks)
  Advanced: 3-6 months multimodal
• 5. Can women retain fertility?
  Yes, Stage IA1-IB1: Radical trachelectomy preserves the uterus (70% success rate), routine ovarian preservation. Egg freezing requires pre-treatment.